z-logo
open-access-imgOpen Access
Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins
Author(s) -
Kojo S.J. ElenitobaJohnson,
David K. Crockett,
Jonathan A. Schumacher,
Stephen D. Jenson,
Cheryl M. Coffin,
Alan L. Rockwood,
Megan S. Lim
Publication year - 2006
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.0506514103
Subject(s) - anaplastic lymphoma kinase , chromosomal translocation , fusion protein , fusion gene , cancer research , anaplastic large cell lymphoma , biology , oncogene proteins , microbiology and biotechnology , lymphoma , gene , genetics , recombinant dna , medicine , regulation of gene expression , pathology , immunology , malignant pleural effusion , lung cancer
The anaplastic lymphoma kinase (ALK) on 2p23 is a tyrosine kinase that forms chimeric fusions with numerous translocation partners. We describe a mass spectrometry-based approach for the identification of ALK fusion partners. This approach accurately identified the nucleophosmin (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line carrying the t(2;5)(p23;q35), and the TPM3-ALK in a clinical biopsy of inflammatory myofibroblastic tumor (IMT) carrying the t(1;2)(q21;p23). This study shows the ability of mass spectrometry to identify oncogenic chimeric proteins resulting from chromosomal rearrangements. This strategy can be adapted for the identification of known and unknown translocation partners of chimeric ALK fusion proteins involved in oncogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom